康希诺(688185) - 2024 Q4 - 年度业绩

Financial Performance - Total revenue for 2024 reached ¥846,338,072.24, a year-on-year increase of 137.01%[4] - Net loss attributable to shareholders decreased to ¥378,884,001.37, a reduction of 74.45% compared to the previous year[6] - The company reported a significant reduction in operating losses by 80.62% and total losses by 80.74%[9] - The basic earnings per share improved to -¥1.53, compared to -¥6.01 in the previous year[4] Assets and Liabilities - Total assets at the end of the reporting period were ¥7,958,132,235.38, a decrease of 14.60% year-on-year[4] Research and Development - Research and development expenses decreased significantly, contributing to improved operational efficiency[7] - The company focused on commercializing the ACYW135 meningococcal polysaccharide conjugate vaccine, which is the only four-valent meningococcal vaccine in the Chinese market[6] Operational Efficiency - The company optimized resource allocation and implemented cost-reduction measures, leading to a notable decrease in asset impairment losses[7] - The sales channel for the meningococcal vaccine was continuously developed, resulting in increased market penetration and sales volume[9] Risk Management - The company emphasizes the importance of monitoring investment risks as the financial data is preliminary and unaudited[10]